Obesity Pharmacotherapy Class Review
Retatrutide achieves weight reductions of 20 to 24 percent in Phase 2 trials, approaching bariatric surgery outcomes (Lempesis and Dalamaga, 2026).
[1]Retatrutide is a synthetic 39-amino-acid peptide triple agonist developed by Eli Lilly that simultaneously activates the GLP-1 receptor, the GIP receptor, and the glucagon receptor. It is the first triple incretin/glucagon receptor agonist to advance through Phase 2 trials and the most clinically aggressive obesity pharmacotherapy in late-stage development, producing weight reductions of 20 to 24 percent at the highest doses.
At a glance
- Type
- Synthetic 39-amino-acid triple agonist (GLP-1, GIP, and glucagon receptors)
- Developer
- Eli Lilly
- Code name
- LY3437943
- Development stage
- Phase 2 completed; Phase 3 trials ongoing for obesity, type 2 diabetes, and obstructive sleep apnea
- Regulatory
- Not FDA approved
- Monitoring
- Baseline and quarterly LFTs; heart rate (5 to 10 bpm elevation expected)
What the research supports
Retatrutide is the most aggressive incretin pharmacotherapy in late-stage development, with weight loss outcomes approaching bariatric surgery and the broadest cardiovascular benefit in the class.
Incretin BP and Mortality Meta-Analysis
85 RCTs, 90,977 participants: triple agonists produce SBP reduction 6.6 mmHg and DBP reduction 2.1 mmHg, the largest BP reductions of any incretin class; all-cause mortality reduced 18 percent across incretin-based therapy.
[2]Triple Receptor Mechanism
GLP-1 effects (appetite, insulin, gastric emptying), GIP effects (insulin, lipid metabolism, adipose), and glucagon effects (energy expenditure, hepatic glucose and lipid modulation) in a single peptide.
Phase 3 Pipeline
Phase 3 trials ongoing for obesity, type 2 diabetes, and obstructive sleep apnea; FDA approval anticipated but not yet granted.
Summary of key findings
Approaching Bariatric Outcomes
20 to 24 percent weight reduction at highest Phase 2 doses approaches bariatric surgery outcomes, making retatrutide the most potent pharmacotherapy in its class.
Triple-Receptor Differentiation
Glucagon receptor activation adds direct energy expenditure and hepatic fat reduction beyond GLP-1/GIP alone, distinguishing retatrutide from tirzepatide and semaglutide.
Largest BP and Mortality Reductions in Class
Triple agonists lead the incretin class for SBP reduction (6.6 mmHg) and deliver an 18 percent all-cause mortality benefit across incretin-based therapy.
Compounded Source Variability
Quality varies significantly given absence of FDA approval and reference standard. Pharmacy verification is essential before initiating therapy.
Dosing guide
From published protocols. Licensed provider supervision assumed throughout.
- Phase 2 Dose Range
- Doses 1, 4, 8, and 12 mg tested; dose-response robust with greater weight loss at higher doses.
- Compounded Titration
- Typically titrates from 1 to 2 mg weekly up to 8 to 12 mg over months, with increases every 4 weeks.
- Excel Maintenance Protocol
- Initial 2 mg weekly; titrate up to 8 to 12 mg weekly. May double dose every 4 weeks until reaching 12 mg, then maintain.
- LFT and HR Monitoring
- Glucagon receptor activation requires baseline and quarterly LFTs; heart rate elevation (5 to 10 bpm) is worth monitoring.
Vial reference
Units are for a U-100 insulin syringe (100 units = 1 mL), computed from the vial concentration.
| Vial | Dose range | Units per dose | Frequency | Notes |
|---|---|---|---|---|
| GLP-1 R 10 mg / 1 mL | 2 to 12 mg | 20 to 120 units | 1x per week | 0.1 mg per unit. Starting dose 2 mg. |
| GLP-1 R 12 mg / 1.2 mL | 2 to 12 mg | 20 to 120 units | 1x per week | 0.1 mg per unit. |
| GLP-1 R 24 mg / 2.4 mL | 2 to 12 mg | 20 to 120 units | 1x per week | 0.1 mg per unit. |
| GLP-1 R 60 mg / 6 mL | 2 to 12 mg | 20 to 120 units | 1x per week | 0.1 mg per unit. |
| Phase 2 dose-response | 1 / 4 / 8 / 12 mg | 1x per week | 4 weeks per step typical. |
Reference ranges as published in the source protocol document, not a prescription. To work out the draw for a specific vial and dose, use the Peptide Calculator.
Bottom line
Retatrutide is the most aggressive obesity pharmacotherapy in late-stage clinical development. Triple agonism at GLP-1, GIP, and glucagon receptors produces 20 to 24 percent weight loss at higher doses, approaching bariatric surgery outcomes. The glucagon receptor activation differentiates retatrutide from tirzepatide and semaglutide by adding direct effects on energy expenditure, hepatic glucose modulation, and hepatic fat reduction.
Position for patients with significant weight to lose, treatment-resistant obesity, or those plateaued on semaglutide or tirzepatide. Heart rate elevation (5 to 10 bpm) is worth monitoring; LFT monitoring matters more than for tirzepatide or semaglutide. Frame regulatory status honestly: not FDA approved as of this writing. Compounded retatrutide quality varies more than for FDA-approved peptides.
Maximum Weight Loss
20 to 24 percent reduction in Phase 2, approaching bariatric outcomes.
Triple Mechanism
GLP-1 plus GIP plus glucagon receptor activation in one peptide.
Largest Class BP Reduction
SBP reduction 6.6 mmHg and 18 percent all-cause mortality reduction.
References
Citations sourced from PubMed and verified against the PubMed record.
- 1Lempesis and Dalamaga, 2026 Obesity Pharmacotherapy Reimagined: Retatrutide 20 to 24 Percent Weight Reduction
- 2Basile et al., 2026 Incretin-Based Therapies on Blood Pressure Meta-Analysis (85 RCTs, 90,977 Participants)
- 3Jastreboff et al., 2023 Retatrutide Phase 2 Obesity Trial
- 4Rosenstock et al., 2023 Retatrutide Phase 2 Type 2 Diabetes Trial
Regulatory status, cautions and contraindications
Regulatory Status
Retatrutide is not FDA approved.
Contraindications
MTC / MEN2 personal or family history is a contraindication. Pregnancy is contraindicated.
Monitoring Requirements
Glucagon receptor activation requires baseline and quarterly LFT monitoring plus heart rate assessment (5 to 10 bpm elevation expected).
Compounded Quality
Compounded retatrutide quality varies significantly. Pharmacy verification is essential given the absence of an FDA-approved reference standard.
Legal disclaimer
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
This peptide overview is for informational purposes only and does not constitute medical advice. The information provided here is not intended to diagnose, treat, cure, or prevent any disease. Peptide therapies should only be used under the guidance of a licensed healthcare provider, who can assess individual health needs and determine appropriate dosing and administration.
Always consult your healthcare provider before starting any new treatment, as misuse or improper dosing may lead to adverse effects. The efficacy and safety of peptide therapies have not been fully established in all cases, and ongoing medical supervision is essential.